MF tricyclic and sulindac retard tumor formation in an animal model

Hadas Dvory-Sobo, Diana Kazanov, Eliezer Liberman, Shlomo Birkenfeld, Benny Bulvik, Pauline Luk, Moshe Leshno, Nadir Arber

Research output: Contribution to journalArticlepeer-review

Abstract

New selective cyclooxygenase-2 inhibitors offer the benefit of cancer protection with less gastrointestinal toxicity associated with nonselective nonsteroidal anti-inflammatory drugs (NSAIDs). We hypothesize that MF tricyclic and sulindac can retard all stages of tumor formation in nude mice. In a blinded placebo controlled study, 3 types of experiments were performed: 1) 2.5 x 106 cells were injected into 2 flanks of nude mice subcutaneously, as a model for in situ cancer (n=192); 2) 1 x 106 cells were injected into the cecum of mice as a model for in situ colorectal cancer (n=78) and 3) 0.5 x 106 cells were implanted into the splenic sub-capsule to establish a colorectal cancer liver metastasis model (n=78). The animals were fed with standard chow containing either placebo, MF tricyclic (67 mg/kg of chow) or sulindac (150 mg/kg of chow). Mice that were given MF tricyclic or sulindac, at clinical anti-inflammatory plasma concentrations, were significantly more tumor free and had significantly smaller primary tumors and fewer metastases, as compared to mice that consumed placebo. The mortality and the latency period were significantly better in the treatment groups. These findings suggest that selective COX-2 inhibitors may serve as an adjunct to standard therapy in colorectal cancer.

Original languageEnglish
Pages (from-to)11-16
Number of pages6
JournalInternational Journal of Cancer
Volume118
Issue number1
DOIs
StatePublished - 1 Jan 2006

Keywords

  • Animal model
  • COX-2 inhibitor
  • Chemo-prevention
  • Colon cancer
  • Sulindac

Fingerprint

Dive into the research topics of 'MF tricyclic and sulindac retard tumor formation in an animal model'. Together they form a unique fingerprint.

Cite this